This article was originally published in The Tan Sheet
Executive SummaryRevenues during the firm's second quarter grew 17.8 % to $19.5 mil., fueled by the strong performance of new the products which more than offset a decline from the discontinuation of Ester-C, the Chatsworth, Calif.-based firm says. The nutritional products company adds it is well-positioned to enter the international marketplace, and is benefiting from the diversification of its business through the recent acquisition of MRI (1"The Tan Sheet" June 18, 2007, p. 7). Operating income jumped 172.9% during the quarter to $737,000 while net income was $4.2 mil. compared to $100,000 in the year-ago period, the firm notes...
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.